NSPR InspireMD

InspireMD to Announce First Quarter 2025 Financial Results

InspireMD to Announce First Quarter 2025 Financial Results

MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.

Webcast:

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit .

Investor Contact:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

Webb Campbell

Gilmartin Group LLC



EN
25/04/2025

Underlying

NSPRInspireMD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InspireMD

 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid St...

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA). The CGuard Prime was engineered specifically to minimize both early and late embolism risk by effectively trapping potential emb...

July 9, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent Syste...

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company’s C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional...

June 24, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevent...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™...

June 13, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces Appointment of Michael Lawless as Chief Financial ...

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial...

June 3, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Reports First Quarter 2025 Financial Results

InspireMD Reports First Quarter 2025 Financial Results Management to host investor conference call today, May 9th, at 8:30am ET MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent...

May 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch